Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
10 01 2023
Historique:
accepted: 12 09 2022
received: 19 05 2022
pubmed: 15 10 2022
medline: 7 1 2023
entrez: 14 10 2022
Statut: ppublish

Résumé

Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized that the mutational status of bone marrow dysplastic cells and leukemic blasts, analyzed at the onset of AML using integrated multidimensional flow cytometry (MFC) immunophenotyping and fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS), could reconstruct leukemogenesis. Dysplastic cells were detected by MFC in 285 of 348 (82%) newly diagnosed patients with AML. Presence of dysplasia according to MFC and World Health Organization criteria had no prognostic value in older adults. NGS of dysplastic cells and blasts isolated at diagnosis identified 3 evolutionary patterns: stable (n = 12 of 21), branching (n = 4 of 21), and clonal evolution (n = 5 of 21). In patients achieving complete response (CR), integrated MFC and FACS with NGS showed persistent measurable residual disease (MRD) in phenotypically normal cell types, as well as the acquisition of genetic traits associated with treatment resistance. Furthermore, whole-exome sequencing of dysplastic and leukemic cells at diagnosis and of MRD uncovered different clonal involvement in dysplastic myelo-erythropoiesis, leukemic transformation, and chemoresistance. Altogether, we showed that it is possible to reconstruct leukemogenesis in ∼80% of patients with newly diagnosed AML, using techniques other than single-cell multiomics.

Identifiants

pubmed: 36240453
pii: 486809
doi: 10.1182/bloodadvances.2022008141
pmc: PMC9811200
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-173

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Nat Commun. 2020 Oct 21;11(1):5327
pubmed: 33087716
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
Blood. 2010 May 6;115(18):3776-86
pubmed: 20203266
Cancer. 2021 Jun 15;127(12):2003-2014
pubmed: 33626197
Leukemia. 2012 Sep;26(9):1908-75
pubmed: 22552007
Leukemia. 2012 Sep;26(9):1986-2010
pubmed: 22948490
Blood Adv. 2021 Sep 14;5(17):3279-3289
pubmed: 34459887
Nature. 2020 Nov;587(7834):477-482
pubmed: 33116311
Blood. 2008 Mar 15;111(6):3173-82
pubmed: 18192505
Blood. 2021 Nov 4;138(18):1733-1739
pubmed: 34115096
Biol Blood Marrow Transplant. 2017 Jul;23(7):1064-1071
pubmed: 28315400
Mod Pathol. 2015 Jul;28(7):965-76
pubmed: 25975285
Blood. 2010 Oct 14;116(15):2742-51
pubmed: 20581309
Br J Haematol. 2021 Mar;192(6):1054-1063
pubmed: 33618432
Nat Med. 2019 Jan;25(1):103-110
pubmed: 30510255
Nat Rev Cancer. 2017 Jan;17(1):5-19
pubmed: 27834397
Leukemia. 2022 Mar;36(3):656-663
pubmed: 34615986
J Pers Med. 2021 Mar 11;11(3):
pubmed: 33799721
Nat Commun. 2021 Dec 13;12(1):7244
pubmed: 34903734
Blood. 2013 Oct 31;122(18):3169-77
pubmed: 24047651
Blood. 2012 Apr 5;119(14):3203-10
pubmed: 22323480
Nature. 2014 Feb 20;506(7488):328-33
pubmed: 24522528
Blood. 2016 Feb 18;127(7):893-7
pubmed: 26631115
Blood Adv. 2020 Mar 10;4(5):943-952
pubmed: 32150611

Auteurs

Catia Simoes (C)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Maria-Carmen Chillon (MC)

Centro de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain.

David Martínez-Cuadrón (D)

Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Maria-José Calasanz (MJ)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
CIMA Lab Diagnostics, Universidad de Navarra, IDISNA, Pamplona, Spain.

María-Belén Vridiales (MB)

Centro de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain.

Iria Vazquez (I)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
CIMA Lab Diagnostics, Universidad de Navarra, IDISNA, Pamplona, Spain.

Montserrat Hernández-Ruano (M)

Centro de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain.

Beñat Ariceta (B)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Paula Aguirre-Ruiz (P)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Leire Burgos (L)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Diego Alignani (D)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Sarai Sarvide (S)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Sara Villar (S)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Ana Alfonso Pierola (AA)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Felipe Prosper (F)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Rosa Ayala (R)

Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain.

Joaquin Martínez-López (J)

Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain.

Juan Miguel Bergua Burgues (JM)

Hospital San Pedro de Alcántara, Cáceres, Spain.

Susana Vives (S)

Hospital Germans Trias i Pujol, Badalona, Spain.

Jose A Perez-Simon (JA)

Hospital Universitario Virgen del Rocio, Seville, Spain.

Maria Garcia-Fortes (M)

Hospital Universitario Virgen de la Victoria, Málaga, Spain.

Teresa Bernal Del Castillo (T)

Hospital Central de Asturias, SPA, IUOPA, Oviedo, Spain.

Mercedes Colorado (M)

Hospital Universitario Marqués de Valdecilla, Cantabria, Spain.

Mayte Olave (M)

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Juan I Rodríguez-Gutiérrez (JI)

Hospital Universitario de Basurto, Bilbao, Spain.

Jorge Labrador (J)

Hospital Universitario de Burgos, Burgos, Spain.

Marcos González (M)

Centro de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain.

Jesús F San-Miguel (JF)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Miguel Ángel Sanz (MÁ)

Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Pau Montesinos (P)

Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Bruno Paiva (B)

Departamento de Hemato-Oncology, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH